by Deutsches Zentrum fuer Diabetesforschung DZD Credit: Norbert Stefan, IDM / DZD About 70% of obese people have metabolic dysfunction-associated steatotic liver disease (MASLD). However, MASLD is also found in lean people. Paradoxically, some effective pharmacological approaches to improve liver health in people with MASLD are associated with no change in body weight or even...
Tag: <span>steatotic liver disease</span>
Post
Mechanism of metabolic dysfunction-associated steatotic liver disease: Important role of lipid metabolism
Xia & He Publishing Inc. image: The raw material for de novo fatty acid synthesis is acetyl-CoA, which can be obtained via the citrate shuttle pathway or from acetic acid. ACC and FASN catalyze the conversion of acetyl-CoA into saturated palmitic acid, which can be further modified into other fatty acids by enzymes such as SCD. De novo fatty...
Post
Pipeline of new drug treatment for non-alcoholic fatty liver disease/metabolic dysfunction-associated steatotic liver disease
News Release 25-Sep-2024 Peer-Reviewed PublicationXia & He Publishing Inc. ACC, Acetyl-CoA Carboxylase; PPAR, peroxisome proliferator–activated receptor; MPC, mitochondrial pyruvate carrier; THR, thyroid hormone receptor; ASK-1, apoptosis signaling kinase-1; GLP-1R, glucagon-like peptide-1 receptor; GCGR, glucagon receptor; GIPR, glucose-dependent insulinotropic polypeptide receptor; PDE, phosphodiesterase; SGLT, sodium–glucose cotransporter; FXR, farnesoid X receptor; SCD1, stearoyl-CoA desaturase 1; FGFR4/1, fibroblast...